Top Markets
Coin of the day
Cortexyme, Inc. Cortexyme, Inc.

Cortexyme, Inc.

CRTX
Rangering i aksjer #25182
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Aksjekurs
$1.95
Sist synkronisert: 2022-07-29
Markedsverdi
$52.48M
Endring (1 dag)
2.63%
Endring (1 år)
0.00%
Land
US
Handel Cortexyme, Inc. (CRTX)

Kategori

EPS for Cortexyme, Inc. (CRTX)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Cortexyme, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Cortexyme, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$-7.98 -
US